HCW Biologics Inc. has announced the conversion of its unsecured convertible promissory notes, amounting to a principal value of $270,000, into common stock. These Convertible Bridge Notes, which were set to mature on May 5, 2026, accrued interest at a rate of 10% per annum. As per the terms of the conversion, the notes were converted into shares of common stock at a final offering price of $7.45 per share, following the company's recent $5.0 million financing closing. Consequently, HCW Biologics issued shares to key figures within the company: Hing C. Wong, the Founder and CEO, received 8,054 shares; Scott T. Garrett, the Chairman of the Board, obtained 13,423 shares; and Gary M. Winer, a Board member, was allocated 1,342 shares. These converted shares will be subject to a 90-day lock-up period. Additionally, holders of the Convertible Bridge Notes are entitled to a portion of the proceeds from the company's shares of Wugen common stock if these shares are sold in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.